{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T12:05:40Z","timestamp":1790856340631,"version":"4.1.0"},"reference-count":28,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"name":"Takeda UK","award":["IISR-2015-101211"],"award-info":[{"award-number":["IISR-2015-101211"]}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Therap Adv Gastroenterol"],"published-print":{"date-parts":[[2026,5]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>VEST was a multi-centre study of real-world use of vedolizumab in inflammatory bowel disease (IBD) in routine practice in the United Kingdom.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives:<\/jats:title>\n                    <jats:p>To describe real-world indications, effectiveness, patient-reported outcomes and safety.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design:<\/jats:title>\n                    <jats:p>Prospective observational cohort study at 22 centres.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>Patients receiving vedolizumab as part of standard care were included. Data were collected at infusion visits for activity indices (Harvey\u2013Bradshaw Index (HBI) or partial Mayo Score (PMS)), physician global assessment (PGA), patient-reported quality-of-life and treatment perception (IBD-Control Questionnaire) and adverse events. Clinical response (Wk14) was defined as a reduction in HBI \u2a7e3 or PMS \u2a7e2, clinical remission as HBI \u2a7d4 or PMS \u2a7d1 and analysed using non-responder imputation. One-year persistence was defined as continuing on vedolizumab after an infusion at \u2a7e48\u2009weeks. Biomarker and endoscopic data were not available.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      364 patients, mean age: 48 years; 132 (36%) with Crohn\u2019s disease (CD), 224 (62%) with UC and 8 (2%) with IBD-U; 174 (48%) male; 142 (39%) receiving steroids at baseline (Wk0); 141 (39%) bio-na\u00efve. At baseline, 279 (77%) had \u201cactive\u201d disease. One-year persistence: 58% overall (54% for active disease). Among persistent cases (\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      \u2009=\u2009212), median (IQR) IBD-Control-8 scores improved from 6 (3\u201310) at baseline to 14 (10\u201316) at post-induction (Wk14) and 1\u2009year (\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      \u2009&lt;\u20090.001 vs baseline). Corresponding scores for IBD-Control-VAS were: 50 (30\u201370), 80 (65\u201390) and 85 (70\u201395), respectively (\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      \u2009&lt;\u20090.001 vs baseline). Each domain of IBD-Control-8 showed improvement. Baseline and post-induction health status (activity index, PGA or IBD-Control) were associated with 1-year persistence, but no significant associations were observed for disease type, duration, bio-na\u00efve status or baseline steroids. Of those with active disease at Wk0, clinical remission rates were 29%, 30% and 38% for CD, UC and IBD-U, respectively, and steroid-free remission rates were 26%, 27% and 38%. Similar remission rates were observed at 1\u2009year. Possible adverse events leading to treatment cessation were rare (3%).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>In routine clinical practice in the UK, vedolizumab demonstrated high levels of persistence. Similar rates of clinical response, remission and 1-year persistence were seen in UC and CD patients, and in bio-experienced versus na\u00efve cases. Persistent cases experienced significant and sustained improvements in quality of life and treatment perception. Persistence does not imply anti-inflammatory efficacy, as biomarker data were not available.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/17562848261446551","type":"journal-article","created":{"date-parts":[[2026,5,31]],"date-time":"2026-05-31T08:06:21Z","timestamp":1780214781000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":2,"title":["The UK vedolizumab real-life experience study in inflammatory bowel disease (VEST): patient characteristics, drug persistence and patient-centred outcomes"],"prefix":"10.1177","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1825-3239","authenticated-orcid":false,"given":"Keith","family":"Bodger","sequence":"first","affiliation":[{"name":"Department of Health Data Science, University of Liverpool, Liverpool, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-2933-0079","authenticated-orcid":false,"given":"Cheryl","family":"Booker","sequence":"additional","affiliation":[{"name":"University Hospital Southampton NHS Foundation Trust, Southampton, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1922-2354","authenticated-orcid":false,"given":"Frederick","family":"Taylor","sequence":"additional","affiliation":[{"name":"Department of Health Data Science, University of Liverpool, Liverpool, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6058-5528","authenticated-orcid":false,"given":"Tariq","family":"Ahmad","sequence":"additional","affiliation":[{"name":"Royal Devon and Exeter NHS Foundation Trust, Exeter, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6361-4662","authenticated-orcid":false,"given":"Stuart","family":"Bloom","sequence":"additional","affiliation":[{"name":"University College London Hospitals NHS Foundation Trust, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey","family":"Butterworth","sequence":"additional","affiliation":[{"name":"The Shrewsbury and Telford Hospital NHS Trust, Shrewsbury, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"VEST Study Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klaartje","family":"Kok","sequence":"additional","affiliation":[{"name":"Barts Health NHS Trust, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8037-793X","authenticated-orcid":false,"given":"Alan","family":"Lobo","sequence":"additional","affiliation":[{"name":"Inflammatory Bowel Disease Centre, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0972-8148","authenticated-orcid":false,"given":"Peter","family":"Irving","sequence":"additional","affiliation":[{"name":"IBD Unit, Guy\u2019s and St Thomas\u2019 Hospital NHS Foundation Trust, London, UK"},{"name":"Microbial Sciences, King\u2019s College London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9659-3247","authenticated-orcid":false,"given":"J. R. Fraser","family":"Cummings","sequence":"additional","affiliation":[{"name":"University Hospital Southampton NHS Foundation Trust, Southampton, SO16 6YD, UK Faculty of Medicine, University of Southampton, Southampton, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2026,5,31]]},"reference":[{"key":"e_1_3_4_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(24)00044-X"},{"key":"e_1_3_4_3_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1215734"},{"key":"e_1_3_4_4_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1215739"},{"key":"e_1_3_4_5_2","doi-asserted-by":"publisher","DOI":"10.3892\/etm.2023.11997"},{"key":"e_1_3_4_6_2","unstructured":"Overview | Vedolizumab for treating moderately to severely active ulcerative colitis | Guidance | NICE [Internet]. NICE https:\/\/www.nice.org.uk\/guidance\/ta342 (2015 accessed 15 July 2024)"},{"key":"e_1_3_4_7_2","unstructured":"Overview | Vedolizumab for treating moderately to severely active Crohn\u2019s disease after prior therapy | Guidance | NICE [Internet]. NICE https:\/\/www.nice.org.uk\/guidance\/ta352 (2015 accessed 15 July 2024)"},{"key":"e_1_3_4_8_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00535-018-1480-0"},{"key":"e_1_3_4_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(80)92767-1"},{"key":"e_1_3_4_10_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198712243172603"},{"key":"e_1_3_4_11_2","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2013-305600"},{"key":"e_1_3_4_12_2","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjad147"},{"key":"e_1_3_4_13_2","unstructured":"IBD-Control Questionnaire [Internet]. IBD-control questionnaire https:\/\/www.ibd-control-questionnaire.com (accessed 15 July 2024)"},{"key":"e_1_3_4_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2007.11.008"},{"key":"e_1_3_4_15_2","doi-asserted-by":"publisher","DOI":"10.1111\/apt.18006"},{"key":"e_1_3_4_16_2","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjx161"},{"issue":"10","key":"e_1_3_4_17_2","first-page":"1583","article-title":"A core outcome set for inflammatory bowel diseases: development and recommendations for implementation in clinical practice through an international multi-stakeholder consensus process","volume":"18","author":"Fierens L","year":"2023","unstructured":"Fierens L, Carney N, Novacek G, et al. A core outcome set for inflammatory bowel diseases: development and recommendations for implementation in clinical practice through an international multi-stakeholder consensus process. J Crohns Colitis 2023; 18(10): 1583\u20131595.","journal-title":"J Crohns Colitis"},{"key":"e_1_3_4_18_2","doi-asserted-by":"publisher","DOI":"10.1080\/00365521.2020.1857430"},{"issue":"6","key":"e_1_3_4_19_2","first-page":"911","article-title":"The IBD-control questionnaire: German translation and validation of the standardized questionnaire for patient reported outcome measurement in inflammatory bowel disease","volume":"60","author":"M\u00fcller A","year":"2021","unstructured":"M\u00fcller A, Bilger SS, G\u00f6ldi A. The IBD-control questionnaire: German translation and validation of the standardized questionnaire for patient reported outcome measurement in inflammatory bowel disease. Z Gastroenterol 2021; 60(6): 911\u2013926.","journal-title":"Z Gastroenterol"},{"issue":"7","key":"e_1_3_4_20_2","first-page":"524","article-title":"Translation into Spanish and validation of a short questionnaire to measure the control of inflammatory bowel disease from the patient\u2019s perspective: IBD-control, EII-control","volume":"45","author":"Vicente Lid\u00f3n R","year":"2022","unstructured":"Vicente Lid\u00f3n R, Garc\u00eda L\u00f3pez S, Corsino Roche P, et al. Translation into Spanish and validation of a short questionnaire to measure the control of inflammatory bowel disease from the patient\u2019s perspective: IBD-control, EII-control. Gastroenterol Hepatol 2022; 45(7): 524\u2013534.","journal-title":"Gastroenterol Hepatol"},{"key":"e_1_3_4_21_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12955-023-02087-0"},{"key":"e_1_3_4_22_2","doi-asserted-by":"publisher","DOI":"10.1111\/jgh.16099"},{"key":"e_1_3_4_23_2","doi-asserted-by":"publisher","DOI":"10.1111\/apt.13852"},{"issue":"4","key":"e_1_3_4_24_2","first-page":"412","article-title":"Long-term efficacy of vedolizumab for Crohn\u2019s disease","volume":"11","author":"Vermeire S","year":"2017","unstructured":"Vermeire S, Loftus EV, Colombel JF, et al. Long-term efficacy of vedolizumab for Crohn\u2019s disease. J Crohns Colitis 2017; 11(4): 412\u2013424.","journal-title":"J Crohns Colitis"},{"issue":"9","key":"e_1_3_4_25_2","first-page":"1272","article-title":"Pharmacological therapy in inflammatory bowel diseases: a narrative review of the past 90\u2009years","volume":"16","author":"Imbrizi M","year":"2023","unstructured":"Imbrizi M, Magro F, Coy CSR. Pharmacological therapy in inflammatory bowel diseases: a narrative review of the past 90\u2009years. Pharm Basel Switz 2023; 16(9): 1272.","journal-title":"Pharm Basel Switz"},{"key":"e_1_3_4_26_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00535-024-02130-x"},{"key":"e_1_3_4_27_2","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjaf157"},{"key":"e_1_3_4_28_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2020.12.031"},{"key":"e_1_3_4_29_2","doi-asserted-by":"publisher","DOI":"10.1002\/ueg2.12572"}],"container-title":["Therapeutic Advances in Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/17562848261446551","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/17562848261446551","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/17562848261446551","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T07:48:11Z","timestamp":1780472891000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/17562848261446551"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":28,"alternative-id":["10.1177\/17562848261446551"],"URL":"https:\/\/doi.org\/10.1177\/17562848261446551","relation":{},"ISSN":["1756-2848","1756-2848"],"issn-type":[{"value":"1756-2848","type":"print"},{"value":"1756-2848","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5]]},"article-number":"17562848261446551"}}